Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2007

View Archived Issues

Valeant's Xyrem launched in Canada for narcoleptics with cataplexy

Lilly receives approval in Japan for Cialis for erectile dysfunction

Paget's disease indication submitted for risedronate sodium hydrate as orphan drug

Cognitive data reported from EPOLYM trial of epoetin alfa

Genentech completes acquisition of Tanox

Gruenenthal claims new analgesic drugs in recent patent literature

Recent patents claim new compounds for the treatment of infectious diseases

New treatment options for psychological disorders described in recent patents

CeNeS grants rights to Ono for new intravenous anesthetic in Japan

Deforolimus new nonproprietary name for Ariad's AP-23573

TURNS network evaluating two different treatments for cognitive impairment in schizophrenia

Kosan enrolls patients in phase II/III trial of Hsp90 inhibitor tanespimycin

Depot formulation of olanzapine provides therapeutic D2 receptor occupancy

Promising results from phase II study of Iomai's patch-based ETEC E. coli vaccine

Phase III studies show Vidaza significantly increases survival in MDS

Novel inhibitors of HIV-1 protease dimerization described

ImmunoGen begins phase II trial of huC242-DM4 for gastric cancer

Regeneron and Bayer begin phase III study of VEGF Trap-Eye for wet AMD

PF-04548043 enters phase I for GERD

Array to initiate phase I trial of ErbB-2 inhibitor ARRY-380 for cancer

Phase II trial of Antisoma's AS-1411 in AML begins

Hana Biosciences begins phase II trial of Marqibo for ALL

Innovive reaches SPA agreement with FDA for pivotal phase II trial of tamibarotene

First approval for Pfizer's novel HIV treatment

NVA-237 progressing through clinical trials for COPD

North American clinical evaluation of GSK prepandemic H5N1 vaccine commences

FDA will review sBLA for Orencia in juvenile arthritis

Lux Biosciences' LX-211 granted fast track designation for the treatment of uveitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...